| |
Abstract |
| Title |
: THE EVALUATION OF A RESPONSE AND AN ADVERSE
EVENTS IN CHRONIC MYELOID LEUKEMIA PATIENTS |
| By |
: RUTDAKORN NUNTAPANICH ARUNTHIDA NOKPEJ |
| Degree |
: DOCTOR OF PHARMACY |
| Advisor |
: MANIT SAETEAW,BCP,BCOP,WANNAPORN WATTANAWONG |
| Keywords |
: CHRONIC MYELOID LEUKEMIA, IMATINIB, NILOTINIB |
| |
|
| Chronic myeloid leukemia(CML) is a result of BCR-ABL gene abnormality leading to overexpression of tyrosine kinase enzyme synthesis. Therefore, Oral Tyrosine Kinase Inhibitors (TKIs) has been developed for treatment. Many clinical studies have shown better efficacy and safety outcomes than conventional chemotherapy. Objectives= The purpose of this study was to evaluate incidences of responders and adverse events from oral TKIs in CML patients. Methods= The retrospective cohort study was conducted in CML patients who were treated with oral chemotherapy during 1st of October 2014 and 31st of March 2015 at Sanpasittiprasong hospital. Responders were determined according to the European Leukemia Net 2013. Incidences of responders and adverse events were reported by using descriptive statistic. Results= 110 patients medical chart were reviewed (69 male and 41 female). Mean age was 48 years. Imatinib and Nilotinib were used in 79 and 31 patients, respectively. 98 patients (89.10%) responded after TKIs treatment (Imatinib 71 patients and Nilotinib 27 patients). Incidences of responder were similar in both TKIs (P value 0.47). Toxicities were observed in 85 patients (77.27%). Hematologic toxicities were reported in 82 patients (Grade 3-4 14 patients). Hematologic toxicities were found in patients who were treated with Imatinib more than Nilotinib (P-value <0.05) especially in anemia and neutropenia. Conclusions= TKIs have shown great efficacy in CML patients. Hematologic toxicity is an important issue need to concern especially during Imatinib treatment. |
| |
|
| Close this window |